Melanoma updates from the CancerNetwork
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Melanoma updates from the CancerNetwork

› Forums › Cutaneous Melanoma Community › Melanoma updates from the CancerNetwork

  • This topic is empty.
  • Post
    • November 28, 2013 at 8:06 pm
    Gene_S
    Participant

       

      Society for Melanoma Research
      Melanoma Therapy Overview at SMR 2013
      Georgina Long, BSc, PhD, MBBS, FRACP
      At the 10th International Congress of the Society for Melanoma Research (SMR), we spoke with Dr. Georgina Long about current targeted approaches for the treatment of advanced-stage melanoma.
      PD-L1 Inhibitor MK-3475 Again Shows Promise in Advanced Melanoma
      Anna Azvolinsky, PhD
      The PD-L1 inhibitor MK-3475 is continuing to show activity and long-term responses in patients with metastatic melanoma, according to results presented at the International Congress of the Society for Melanoma Research.
      Anti-PD-L1 Antibody MPDL3280A Active in Metastatic Melanoma
      Anna Azvolinsky, PhD
      About one-third of patients with advanced cutaneous melanoma treated with MPDL3280A, an antibody against the programmed death 1 ligand (anti-PD-L1) showed a response in a phase I clinical trial.
      Combination of BRAF and PI3K Inhibitors Explored in Melanoma
      Cancer Network Editors
      Preliminary data from a combination trial of vemurafenib plus PX-866, a nonreversible pan-PI3 kinase inhibitor were presented at the 10th International Congress of the Society for Melanoma Research (SMR) held in Philadelphia.
      Targeted Therapy Combo Boosts Survival for Advanced Melanoma Patients
      Cancer Network Editors
      Metastatic melanoma patients treated with a dabrafenib/trametinib combination experienced a 3.6-month increase in overall survival compared with patients treated with dabrafenib alone. The results were not statistically significant, partly due to the crossover design of the trial.

       

    Tagged: 

    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

    Popular Topics